Targeting senescence as an anticancer therapy
L Bousset, J Gil - Molecular Oncology, 2022 - Wiley Online Library
Cellular senescence is a stress response elicited by different molecular insults. Senescence
results in cell cycle exit and is characterised by multiple phenotypic changes such as the …
results in cell cycle exit and is characterised by multiple phenotypic changes such as the …
Crosstalk between 5-methylcytosine and N6-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in …
Y Tian, H Xiao, Y Yang, P Zhang, J Yuan, W Zhang… - Molecular cancer, 2023 - Springer
Background Accumulated evidence highlights the significance of the crosstalk between
epigenetic and epitranscriptomic mechanisms, notably 5-methylcytosine (5mC) and N6 …
epigenetic and epitranscriptomic mechanisms, notably 5-methylcytosine (5mC) and N6 …
Therapeutic potential of targeting polo-like kinase 4
Q Lei, Q Yu, N Yang, Z Xiao, C Song, R Zhang… - European Journal of …, 2024 - Elsevier
Abstract Polo-like kinase 4 (PLK4), a highly conserved serine/threonine kinase, masterfully
regulates centriole duplication in a spatiotemporal manner to ensure the fidelity of …
regulates centriole duplication in a spatiotemporal manner to ensure the fidelity of …
Discovery of the First Potent, Selective, and In Vivo Efficacious Polo-like Kinase 4 Proteolysis Targeting Chimera Degrader for the Treatment of TRIM37-Amplified …
Polo-like kinase 4 (PLK4) is a master regulator of centriole replication and has been
proposed as a therapeutic target for multiple cancers, especially TRIM37-amplified breast …
proposed as a therapeutic target for multiple cancers, especially TRIM37-amplified breast …
Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML
Acute myeloid leukemia (AML) with TP53 mutation is one of the most lethal cancers and
portends an extremely poor prognosis. Based on in silico analyses of druggable genes and …
portends an extremely poor prognosis. Based on in silico analyses of druggable genes and …
[HTML][HTML] Cell cycle inhibitors activate the hypoxia-induced DDX41/STING pathway to mediate antitumor immune response in liver cancer
PY Wong, CYK Chan, HDG Xue, CC Goh… - JCI …, 2024 - pmc.ncbi.nlm.nih.gov
Cell cycle inhibitors have a long history as cancer treatment. Here, we report that these
inhibitors combated cancer partially via the stimulator of IFN genes (STING) signaling …
inhibitors combated cancer partially via the stimulator of IFN genes (STING) signaling …
Inhibition of CAF-1 histone chaperone complex triggers cytosolic DNA and dsRNA sensing pathways and induces intrinsic immunity of hepatocellular carcinoma
VWH Yuen, J Shen, DWC Chin, CT Law, BPY Wong… - Hepatology, 2024 - journals.lww.com
Hepatology AASLD Publications Hepatology Liver Transplantation Clinical Liver Disease
Hepatology Communications Log in or Register Subscribe to journalSubscribe Get new issue …
Hepatology Communications Log in or Register Subscribe to journalSubscribe Get new issue …
Discovery of CZS-241: A potent, selective, and orally available polo-like kinase 4 inhibitor for the treatment of chronic myeloid leukemia
Recent studies demonstrate that PLK4 has emerged as a therapeutic target for the treatment
of multiple cancers owing to its indispensable role in cell division. Herein, starting from …
of multiple cancers owing to its indispensable role in cell division. Herein, starting from …
NL13, a novel curcumin analogue and polo like kinase 4 inhibitor, induces cell cycle arrest and apoptosis in prostate cancer models
X Qiao, K Zheng, L Ye, J Yang, R Cui… - British Journal of …, 2024 - Wiley Online Library
Abstract Background and Purpose Prostate cancer remains a major public health burden
worldwide. Polo like kinase 4 (PLK4) has emerged as a promising therapeutic target in …
worldwide. Polo like kinase 4 (PLK4) has emerged as a promising therapeutic target in …
CEP192 is a novel prognostic marker and correlates with the immune microenvironment in hepatocellular carcinoma
Y Liu, W Liang, Y Chang, Z He, M Wu, H Zheng… - Frontiers in …, 2022 - frontiersin.org
Hepatocellular carcinoma (HCC) responds poorly to standard chemotherapy or targeted
therapy; hence, exploration for novel therapeutic targets is urgently needed. CEP192 protein …
therapy; hence, exploration for novel therapeutic targets is urgently needed. CEP192 protein …